Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6 Month 2 through 6 [clinicaltrials_resource:d6d3bd6f7344b9dc1a859c5e0eee13aa]
Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test at Month (Mo) 2, 3, and 6. The analysis was performed according to a life table method. Subjects who withdrew without peak-stimulated luteinizing hormone >= 4 mIU/mL were censored at their last measurement of peak-stimulated luteinizing hormone.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6 Month 2 through 6 [clinicaltrials_resource:d6d3bd6f7344b9dc1a859c5e0eee13aa]
Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test at Month (Mo) 2, 3, and 6. The analysis was performed according to a life table method. Subjects who withdrew without peak-stimulated luteinizing hormone >= 4 mIU/mL were censored at their last measurement of peak-stimulated luteinizing hormone.
Bio2RDF identifier
d6d3bd6f7344b9dc1a859c5e0eee13aa
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d6d3bd6f7344b9dc1a859c5e0eee13aa
measure [clinicaltrials_vocabulary:measure]
Percentage of Participants Wit ...... ) From Month 2 Through Month 6
time frame [clinicaltrials_vocabulary:time-frame]
Month 2 through 6
description
Percentage of participants wit ...... timulated luteinizing hormone.
identifier
clinicaltrials_resource:d6d3bd6f7344b9dc1a859c5e0eee13aa
title
Percentage of Participants Wit ...... ough Month 6 Month 2 through 6
@en
type
label
Percentage of Participants Wit ...... 3bd6f7344b9dc1a859c5e0eee13aa]
@en